# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Jennifer Kim reiterates Precigen (NASDAQ:PGEN) with a Overweight.
Stifel analyst Benjamin Burnett maintains Precigen (NASDAQ:PGEN) with a Buy and maintains $7 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price t...
Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by...
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies...
JP Morgan analyst Brian Cheng downgrades Precigen (NASDAQ:PGEN) from Neutral to Underweight.
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...
JMP Securities analyst Jason Butler reiterates Precigen (NASDAQ:PGEN) with a Market Outperform and maintains $14 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price t...